TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $800.00.
Tyler Van Buren’s rating is based on a combination of factors including an updated model for Regeneron ahead of the first quarter 2025 earnings per share report. Despite significant reductions in the Eylea franchise estimates due to anticipated challenges and a slight decrease in annual Libtayo estimates, Van Buren maintains a positive outlook on the stock. The price target was adjusted to $800, reflecting these changes, but the Buy rating suggests confidence in Regeneron’s ability to navigate competitive pressures.
Van Buren’s analysis indicates that while there are expected headwinds for Eylea, the overall potential and strategic positioning of Regeneron support a favorable investment outlook. The adjustments in sales projections for future years are seen as manageable within the broader context of the company’s growth strategy, justifying the Buy recommendation.
Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Moderna. According to TipRanks, Van Buren has an average return of -6.3% and a 36.59% success rate on recommended stocks.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $850.00 price target.